Marc Schrader - Santhera Pharmaceuticals Head Operations
SPHDF Stock | USD 9.42 0.00 0.00% |
Insider
Marc Schrader is Head Operations of Santhera Pharmaceuticals Holding
Phone | 41 61 906 89 50 |
Web | https://www.santhera.com |
Santhera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4918) % which means that it has lost $0.4918 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (13.1615) %, meaning that it generated substantial loss on money invested by shareholders. Santhera Pharmaceuticals' management efficiency ratios could be used to measure how well Santhera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Robert MD | MeiraGTx Holdings PLC | 62 | |
FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
Karen Cashmere | ZyVersa Therapeutics | 73 | |
Jennifer Lachey | Keros Therapeutics | 51 | |
Aseem Ansari | Design Therapeutics | N/A | |
Julia Wilson | Achilles Therapeutics PLC | N/A | |
Keith MBA | Keros Therapeutics | 55 | |
FAAD MBA | AnaptysBio | 47 | |
Jeffrey Hager | Ideaya Biosciences | 59 | |
Pierre Broqua | Inventiva Sa | 63 | |
Jasbir Seehra | Keros Therapeutics | 69 | |
Pablo MD | ZyVersa Therapeutics | N/A | |
Michel MD | MeiraGTx Holdings PLC | N/A | |
Iraj Ali | Achilles Therapeutics PLC | 50 | |
Dennis Mulroy | AnaptysBio | 70 | |
CPA CMA | Lexaria Bioscience Corp | 63 | |
Matthew MD | Ideaya Biosciences | N/A | |
Simon MBBS | Keros Therapeutics | 54 | |
Vanessa Carle | Lexaria Bioscience Corp | N/A | |
Pr Staels | Genfit | 62 | |
Thomas Baetz | Genfit | 51 |
Management Performance
Return On Equity | -13.16 | |||
Return On Asset | -0.49 |
Santhera Pharmaceuticals Leadership Team
Elected by the shareholders, the Santhera Pharmaceuticals' board of directors comprises two types of representatives: Santhera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santhera. The board's role is to monitor Santhera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Santhera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santhera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Eva Kalias, Head Communications | ||
Shabir MD, Chief Officer | ||
FCMA CGMA, Chief Officer | ||
Thomas Meier, CEO and Head of the Executive Management Team | ||
Dario Eklund, Chief Officer | ||
Gnther Metz, Head VP | ||
Neville MD, Head Management | ||
Sarah HolmesKlotz, Head Culture | ||
Oliver Strub, Sr. VP, General Counsel and Secretary | ||
Marc Schrader, Head Operations |
Santhera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santhera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -13.16 | |||
Return On Asset | -0.49 | |||
Operating Margin | (386.18) % | |||
Current Valuation | 60.45 M | |||
Shares Outstanding | 61.81 M | |||
Shares Owned By Insiders | 18.77 % | |||
Shares Owned By Institutions | 3.50 % | |||
Price To Earning | (6.80) X | |||
Price To Book | 2.75 X | |||
Price To Sales | 469.19 X |
Currently Active Assets on Macroaxis
BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin | |
ADA | Cardano | |
XRP | XRP |
Other Information on Investing in Santhera Pink Sheet
Santhera Pharmaceuticals financial ratios help investors to determine whether Santhera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santhera with respect to the benefits of owning Santhera Pharmaceuticals security.